NCT02547974 - A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults. | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Respiratory Disorders

Interventions

BIOLOGICAL

Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A

2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule

BIOLOGICAL

Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A

2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule

BIOLOGICAL

Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A

2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule

DRUG

Placebo

2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule

Trial Locations (3)

GSK Investigational Site, Wilrijk

GSK Investigational Site, Leuven

GSK Investigational Site, Ghent